A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.

Pereira, Maria J; Lundkvist, Per; Kamble, Prasad G; Lau, Joey; Martins, Julian G; Sjöström, C David; Schnecke, Volker; Walentinsson, Anna; Johnsson, Eva; Eriksson, Jan W

Pereira, Maria J; Lundkvist, Per; Kamble, Prasad G; Lau, Joey; Martins, Julian G; Sjöström, C David; Schnecke, Volker; Walentinsson, Anna; Johnsson, Eva; Eriksson, Jan W.

Afiliação

Pereira MJ; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Lundkvist P; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Kamble PG; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Lau J; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Martins JG; Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
Sjöström CD; inScience Communications, Springer Healthcare, Paris, France.
Schnecke V; AstraZeneca Gothenburg, Mölndal, Sweden.
Walentinsson A; AstraZeneca Gothenburg, Mölndal, Sweden.
Johnsson E; AstraZeneca Gothenburg, Mölndal, Sweden.
Eriksson JW; AstraZeneca Gothenburg, Mölndal, Sweden.

Diabetes Ther ; 9(4): 1511-1532, 2018 Aug.

Article em En | MEDLINE | ID: mdl-29949016

Palavras-chave

Dapagliflozin; Exenatide; Lipid metabolism; Obesity; Single-nucleotide polymorphism; Weight loss

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google